IRSJD collaborates in the new biomedical proteomics unit led by IRB Barcelona

The Institute of Research in Biomedicine, together with the Institut de Recerca Sant Joan de Déu, Josep Carreras Leukemia Research Institute, Vall d'Hebron Institute of Oncology and the University of Barcelona, receives ERDF support to acquire cutting-edge technology in the field of proteomics.

Proteomics is the large-scale study of the proteome, that is to say, all the proteins of an organism. It is used to identify, quantify, and study the structure of proteins and their cellular interaction networks. In both health and disease, proteins are the molecules responsible for carrying out the activities dictated by genes, and the potential alterations that the later may carry. Proteins are therefore ultimately responsible for the proper function or malfunction of cellular processes and are a key study tool and an obvious therapeutic target.

IRB Barcelona's Mass Spectrometry and Proteomics Core Facility, led by Marta Vilaseca and formed by a research team with extensive expertise in the field, has received funding from the Government of Catalonia, through the European Regional Development Fund (ERDF), to purchase next-generation instrumentation for protein analysis, jointly with the Institut de Recerca Sant Joan de Déu (IRSJD), Josep Carreras Leukemia Research Institute (IJC), the Vall d'Hebron Institute of Oncology (VHIO) and the University of Barcelona (UB).

Granted by the Secretariat of Universities and Research of the Department of Enterprise and Knowledge of the Government of Catalonia, ERDF resources aim to provide the scientific community with equipment and platforms that enhance scientific and technological excellence. The project has a cost of €1.039 M, of which the ERDF covers 50% while the remaining 50% is provided by the participating entities.

A service available to the entire scientific community

Housed in the facilities of IRB Barcelona at the Barcelona Science Park, the equipment will serve the scientific community of the same Institute, FIJC, FSJD, VHIO and UB, and will also be available to researchers from other entities that may require the service, such as hospitals, companies and research centres.

More information

IRB Barcelona leads a biomedical proteomics unit to boost personalised medicine. IRB Barcelona.

The equipment is expected to arrive at the facility by early 2021 and to be working at full capacity by 2022.